These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 29196768

  • 1. Macular Atrophy Development and Subretinal Drusenoid Deposits in Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular Degeneration.
    Zarubina AV, Gal-Or O, Huisingh CE, Owsley C, Freund KB.
    Invest Ophthalmol Vis Sci; 2017 Dec 01; 58(14):6038-6045. PubMed ID: 29196768
    [Abstract] [Full Text] [Related]

  • 2. Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial.
    Fan W, Abdelfattah NS, Uji A, Lei J, Ip M, Sadda SR, Wykoff CC, TREX-AMD Study Group.
    Graefes Arch Clin Exp Ophthalmol; 2018 Mar 01; 256(3):511-518. PubMed ID: 29374796
    [Abstract] [Full Text] [Related]

  • 3. Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Sadda SR, Abdelfattah NS, Lei J, Shi Y, Marion KM, Morgenthien E, Gune S, Balasubramanian S.
    Ophthalmology; 2020 Oct 01; 127(10):1360-1370. PubMed ID: 32402555
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes.
    Gharbiya M, Giustolisi R, Marchiori J, Bruscolini A, Mallone F, Fameli V, Nebbioso M, Abdolrahimzadeh S.
    Curr Eye Res; 2018 Mar 01; 43(3):391-396. PubMed ID: 29166140
    [Abstract] [Full Text] [Related]

  • 5. MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen.
    Mantel I, Dirani A, Zola M, Parvin P, De Massougnes S, Bergin C.
    Retina; 2019 May 01; 39(5):906-917. PubMed ID: 29370035
    [Abstract] [Full Text] [Related]

  • 6. Progression of macular atrophy in patients undergoing anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Cho HJ, Park SM, Kim J, Nah SK, Lee J, Lee DW, Kim JW.
    Acta Ophthalmol; 2021 Jun 01; 99(4):e540-e546. PubMed ID: 32996674
    [Abstract] [Full Text] [Related]

  • 7. Effect of Pro Re Nata Regimen with Anti-VEGF on Type 3 Macular Neovascularization: Long-Term Outcomes.
    Toto L, Viggiano P, Quarta A, Grassi M, De Nicola C, Aloia R, D'Aloisio R, Boscia G, Boscia F, Porreca A, Di Nicola M, Savastano MC, Mastropasqua R.
    Ophthalmic Res; 2024 Jun 01; 67(1):282-291. PubMed ID: 38621369
    [Abstract] [Full Text] [Related]

  • 8. PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: An Optical Coherence Tomographic Angiography Analysis.
    Christenbury JG, Phasukkijwatana N, Gilani F, Freund KB, Sadda S, Sarraf D.
    Retina; 2018 Jul 01; 38(7):1276-1288. PubMed ID: 28723848
    [Abstract] [Full Text] [Related]

  • 9. REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Dolz-Marco R, Phasukkijwatana N, Sarraf D, Freund KB.
    Retina; 2017 Feb 01; 37(2):222-233. PubMed ID: 27627752
    [Abstract] [Full Text] [Related]

  • 10. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
    Spooner KL, Fraser-Bell S, Cozzi M, Staurenghi G, Invernizzi A, Monteduro D, Munk MR, Hong T, Chang AA.
    Ophthalmology; 2020 Dec 01; 127(12):1663-1673. PubMed ID: 32544561
    [Abstract] [Full Text] [Related]

  • 11. Intraocular Vascular Endothelial Growth Factor Levels in Pachychoroid Neovasculopathy and Neovascular Age-Related Macular Degeneration.
    Hata M, Yamashiro K, Ooto S, Oishi A, Tamura H, Miyata M, Ueda-Arakawa N, Takahashi A, Tsujikawa A, Yoshimura N.
    Invest Ophthalmol Vis Sci; 2017 Jan 01; 58(1):292-298. PubMed ID: 28114590
    [Abstract] [Full Text] [Related]

  • 12. Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration.
    Munk MR, Ceklic L, Ebneter A, Huf W, Wolf S, Zinkernagel MS.
    Acta Ophthalmol; 2016 Dec 01; 94(8):e757-e764. PubMed ID: 27417506
    [Abstract] [Full Text] [Related]

  • 13. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial.
    Abdelfattah NS, Al-Sheikh M, Pitetta S, Mousa A, Sadda SR, Wykoff CC, Treat-and-Extend Age-Related Macular Degeneration Study Group.
    Ophthalmology; 2017 Feb 01; 124(2):215-223. PubMed ID: 27863845
    [Abstract] [Full Text] [Related]

  • 14. Spectral-Domain OCT-Based Prevalence and Progression of Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Gune S, Abdelfattah NS, Karamat A, Balasubramanian S, Marion KM, Morgenthien E, Sadda SR.
    Ophthalmology; 2020 Apr 01; 127(4):523-532. PubMed ID: 31718842
    [Abstract] [Full Text] [Related]

  • 15. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
    Wada I, Oshima Y, Shiose S, Kano K, Nakao S, Kaizu Y, Yoshida S, Ishibashi T, Sonoda KH.
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul 01; 257(7):1411-1418. PubMed ID: 31119425
    [Abstract] [Full Text] [Related]

  • 16. Neovascularization in Fellow Eye of Unilateral Neovascular Age-related Macular Degeneration According to Different Drusen Types.
    Lee J, Choi S, Lee CS, Kim M, Kim SS, Koh HJ, Lee SC, Byeon SH.
    Am J Ophthalmol; 2019 Dec 01; 208():103-110. PubMed ID: 31377285
    [Abstract] [Full Text] [Related]

  • 17. Intralesional Macular Atrophy in Anti-Vascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration in the IVAN Trial.
    Bailey C, Scott LJ, Rogers CA, Reeves BC, Hamill B, Peto T, Chakravarthy U, Harding SP, writing committee for the IVAN Study Group.
    Ophthalmology; 2019 Jan 01; 126(1):75-86. PubMed ID: 30301555
    [Abstract] [Full Text] [Related]

  • 18. MACULAR ATROPHY FINDINGS BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY COMPARED WITH FUNDUS AUTOFLUORESCENCE IN TREATED EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Takasago Y, Shiragami C, Kobayashi M, Osaka R, Ono A, Yamashita A, Tsujikawa A, Hirooka K.
    Retina; 2019 Feb 01; 39(2):296-302. PubMed ID: 29190232
    [Abstract] [Full Text] [Related]

  • 19. IMPLICATIONS OF THE MORPHOLOGIC PATTERNS OF TYPE 1 MACULAR NEOVASCULARIZATION ON MACULAR ATROPHY GROWTH ON PATIENTS UNDER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT.
    Cabral D, Coscas F, Pereira T, Laiginhas R, Rodrigues C, Français C, Nogueira V, Falcão M, Miere A, Lupidi M, Coscas G, Souied E.
    Retina; 2021 Feb 01; 41(2):287-295. PubMed ID: 32355125
    [Abstract] [Full Text] [Related]

  • 20. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying GS, Huang J, Martin DF, Jaffe GJ, Comparison of Age-related Macular Degeneration Treatments Trials Research Group.
    Ophthalmology; 2016 Apr 01; 123(4):865-75. PubMed ID: 26783095
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.